## CITATION REPORT List of articles citing

Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer

DOI: 10.1002/1097-0142(19920701)70:13.0.co;2-5 Cancer, 1992, 70, 161-8.

Source: https://exaly.com/paper-pdf/23715995/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
102	Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. <i>Cancer</i> , <b>1993</b> , 71, 2574-80	6.4	103
101	Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. <i>Cancer</i> , <b>1993</b> , 72, 3020-8	6.4	68
100	Role of postradical prostatectomy irradiation in carcinoma of the prostate. <b>1993</b> , 3, 198-209		12
99	Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. <b>1993</b> , 19, 229	-60	16
98	Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. <b>1993</b> , 42, 383-9		27
97	Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. <b>1993</b> , 42, 243-8		27
96	The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. <b>1993</b> , 149, 272	2-5	26
95	Nuclear shape and prognosis following orchiectomy in stage D2 prostate cancer. <b>1994</b> , 24, 306-12		3
94	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. <b>1994</b> , 25, 249-65		70
93	Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. <i>Cancer</i> , <b>1994</b> , 74, 2996-3001	6.4	15
92	Prostatic carcinoma: a multivariate analysis of prognostic factors. <b>1994</b> , 69, 924-30		30
91	Prognostic criteria in patients with stage D2 prostate cancer. Correlation with mean nuclear volume. <i>Cancer</i> , <b>1995</b> , 76, 91-5	6.4	8
90	The role of nuclear morphometry for predicting disease outcome in patients with localized renal cell carcinoma. <i>Cancer</i> , <b>1995</b> , 76, 1440-4	6.4	20
89	Nucleolar organizer regions in low- and high-grade carcinomas of the prostate. <b>1995</b> , 13, 195-9		2
88	Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. <b>1995</b> , 27, 102-9		83
87	Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas. <b>1995</b> , 27, 110-7		18
86	Prostate cancerwhat should be studied?. <b>1995</b> , 31A, 1565-6		5

85	Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. <b>1995</b> , 191, 381-90		20
84	Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. <b>1996</b> , 48, 685-91		42
83	The architectural organization of nuclear metabolism. <b>1995</b> , 162A, 67-123		118
82	Stereologically estimated mean nuclear volume of prostatic cancer is a reliable prognostic parameter. <b>1997</b> , 76, 234-7		9
81	The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. <b>1997</b> , 158, 171-4		88
80	Intratumoral nuclear morphologic heterogeneity in prostate cancer. <b>1997</b> , 49, 652-7		23
79	Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. <b>1997</b> , 50, 800-8		24
78	Minimal criteria for the diagnosis of prostate cancer on needle biopsy. <b>1997</b> , 1, 104-29		15
77	Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. <i>Cancer</i> , <b>1997</b> , 79, 772-9	6.4	150
76	Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. <i>Cancer</i> , <b>1997</b> , 79, 1172-9	6.4	26
75	Detectable tumor cells in the blood and bone marrow: smoke or fire?. Cancer, 1998, 83, 394-8	6.4	8
74	Combining volume-weighted mean nuclear volume with Gleason score and clinical stage to predict more reliably disease outcome of patients with prostate cancer. <b>1998</b> , 37, 63-9		7
73	Nuclear dreams: The malignant alteration of nuclear architecture. <b>1998</b> , 70, 172-180		61
72	Human cervical cancer-associated nuclear matrix proteins. <b>1998</b> , 244, 14-25		10
71	Age-related prostate cancer metastases. <b>1998</b> , 51, 985-90		43
70	Markov optical texture parameters as prognostic indicators in ovarian carcinoma. <b>1999</b> , 9, 317-321		6
69	The use of nuclear morphometry for the prediction of survival in patients with advanced cancer of the larynx. <b>1999</b> , 256, 257-61		9
68	Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. <b>1999</b> , 84, 594-7		9

67	Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. <b>1999</b> , 38, 278-84	31
66	E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. <b>1999</b> , 53, 707-13	129
65	Comparison of nuclear morphometric results between needle biopsy and surgical specimens from patients with prostate cancer. <b>1999</b> , 54, 763-6	10
64	Nuclear shape and nuclear matrix protein composition in prostate and seminal vesicles. <b>1999</b> , 54, 934-9	2
63	Nuclear morphometry for the prediction of regional lymph nodes metastases in patients with cancer of the larynx. <b>2000</b> , 123, 770-4	2
62	Analysis of the mechanism of discrepant nuclear morphometric results comparing preoperative biopsy and prostatectomy specimens. <b>2000</b> , 56, 342-5	4
61	Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters?. <b>2000</b> , 55, 377-81	15
60	Pathologic assessment of the surgical specimen. <b>2001</b> , 28, 567-94	73
59	Indicators of pathologic stage of prostate cancer and their use in clinical practice. 2001, 28, 443-58	14
58	Prostate pathology: histologic and molecular perspectives. <b>2001</b> , 15, 407-21	9
57	Does age influence the behaviour of localized prostate cancer?. <b>2001</b> , 87, 629-37	22
56	Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. <b>2001</b> , 48, 274-84	24
55	Prediction of prostate carcinoma stage by quantitative biopsy pathology. <i>Cancer</i> , <b>2001</b> , 91, 2322-2328 6.4	28
54	Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. <b>2002</b> , 59, 715-20	20
53	Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage. <b>2002</b> , 48, 1828-1834	28
52	Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. <b>2002</b> , 42, 139-46	4
52 51		4

49	Molecular and genetic prognostic factors of prostate cancer. <b>2003</b> , 21, 265-74	15
48	Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. <i>Cancer</i> , <b>2003</b> , 98, 2583-91	34
47	Nuclear envelope irregularity is induced by RET/PTC during interphase. <b>2003</b> , 163, 1091-100	48
46	Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. <b>2004</b> , 10, 3465-73	44
45	Molecular aspects of diagnostic nucleolar and nuclear envelope changes in prostate cancer. <b>2004</b> , 91, 170-84	49
44	[Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer]. 2004, 28, 298-307	6
43	Risk stratification after radical prostatectomy in men with pathologically organ-confined prostate cancer using volume-weighted mean nuclear volume. <b>2005</b> , 64, 217-23	3
42	Relationship of age to outcome and clinicopathologic findings in men submitted to radical prostatectomy. <b>2005</b> , 31, 534-9; discussion 539-40	5
41	Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. <b>2005</b> , 34-63	169
40	[Impact of age and comorbidity on survival and toxicity of irradiated prostate cancer patients]. <b>2005</b> , 125, 121-6	1
39	Prognostic factors in prostate cancer. <b>2006</b> , 1, 4	56
38	Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer. <b>1999</b> , 83, 47-52	2
37	Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. <b>2008</b> , 68, 183-9	21
36	Editorial Comment. <b>2009</b> , 181, 94-94	
35	Theranostic and prognostic biomarkers: genomic applications in urological malignancies. <b>2010</b> , 42, 384-94	38
34	Baltasar Llopis Mfiguez (1934-1990). Pionero en la investigacifi del cficer vesical y en la introduccifi de la informfica en Urologfi. <b>2010</b> , 34, 158-164	
33	Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy. <b>2010</b> , 70, 1333-9	21
32	Novel diagnostic biomarkers for prostate cancer. <b>2010</b> , 1, 150-77	155

31	Prognostic factors affecting progression and survival in metastatic prostate cancer. <b>2010</b> , 84, 159-63	15
30	[Baltasar Llopis Mfiguez (1934-1990). A pioneer in research on bladder cancer and introduction of computing in Urology]. <b>2010</b> , 34, 158-64	
29	Immunohistology of the Prostate, Bladder, Kidney, and Testis. <b>2011</b> , 593-661	2
28	Quantitative characterization of preneoplastic progression using single-cell computed tomography and three-dimensional karyometry. <b>2011</b> , 79, 25-34	20
27	Nuclear morphometry, nucleomics and prostate cancer progression. <b>2012</b> , 14, 375-84	19
26	Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. <b>2013</b> , 137, 610-7	60
25	Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies. <b>2013</b> , 8, e69457	10
24	Histomorphometry of Digital Pathology: Case Study in Prostate Cancer. <b>2014</b> , 301-325	
23	Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score $3 + 4 = 7$ prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. <b>2015</b> , 467, 437-42	51
22	Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. <i>Cancer</i> , <b>2015</b> , 121, 3240-51	72
21	Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. <b>2015</b> , 75, 218-24	11
20	Nuclear morphometry in histological specimens of canine prostate cancer: Correlation with histological subtypes, Gleason score, methods of collection and survival time. <b>2017</b> , 114, 212-217	4
19	Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review. <b>2019</b> , 9, e029149	7
18	Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. <b>2019</b> , 16, e1002758	27
17	Nuclear envelope invaginations and cancer. <b>2014</b> , 773, 523-35	19
16	Prostate cancer. <b>2011</b> , 727, 265-90	7
15	Circulating Tumor Cells: High-Throughput Imaging of CTCs and Bioinformatic Analysis. <b>2020</b> , 215, 89-104	4
14	Pathologie. <b>1998</b> , 3-59	O

## CITATION REPORT

13	Improved prediction of prostate cancer recurrence through systems pathology. 2007, 117, 1876-83	91
12	Nuclear features in oral squamous cell carcinoma: A computer-assisted microscopic study. <b>2011</b> , 15, 177-81	14
11	Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. <b>2000</b> , 124, 995-1000	201
10	Tumoren der Prostata. <b>1993</b> , 105-160	
9	Androgen Receptors in Human Prostate Cancer. <b>1994</b> , 239-265	
8	Benign and malignant prostatic neoplasms: human studies. <b>1994</b> , 49, 293-331	7
7	Beyond the nerve-sparing radical prostatectomy. <b>1996</b> , 88, 129-45	
6	Prostate Cancer. <b>1997</b> , 305-315	
5	CAN LEVELS OF URINARY MATRIX METALLOPROTEINASES (MMPS) ACT AS AN ALTERNATIVE TO GLEASON® SCORING IN PROSTATIC MALIGNANCIES. <b>2017</b> , 6, 1281-1285	
4	Prostate Cancer. <b>2003</b> , 455-467	O
3	Pathology of Incipient Neoplasia. <b>2005</b> , 69-96	
2	Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , <b>2018</b> , 6, 43-54	4
1	Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2132554	4 4